Firm News



NEW YORK, April 17, 2014 (GLOBE NEWSWIRE) — JSBarkats, PLLC ( ), announced today the participation of Sunny J. Barkats, Esq., at the Growth Capital Expo to be held at The Caesars Palace in Las Vegas, Nevada, from April 29 to May 1, 2014. For more info see:

“This panel will bring some light on how capital formation could be achieved through Regulation A and discuss the pros and cons of such a raise, I expect a high level of energy and experience from our various panelists, especially when passionate speakers like Sunny are on the panel,” commented M. Teresa Daley, Esq Head of Litigation at JSBarkats.

Mr. Barkats has been speaking and educating bankers and entrepreneurs all around the nation with regards to the JOBS Act, and particularly, Title IV under the Act. He also recently made another appearance on Fox Business News about some of the JOBS Act potential ramifications on the economy and the SEC delays with regards to its implementations.

Sunny J. Barkats is the founding Partner of JSBarkats PLLC, one of the fastest growing small cap law firms in the New York Metro area. As a leading corporate and securities attorney in New York City, Mr. Barkats is advocating the benefits of Reg. A offerings combined with a DPO (Direct Public Offerings), a process also known as DAPO, as the principal catalyst for “Democratization of Capitalism” and capital formation. JSBarkats provides high-value, expert legal counsel in all matters of corporate, capital markets and securities law, representing start-ups as well as established small cap public companies leading a strong team of 20 top notch lawyers and advisors.

The Growth Capital Expo brings together the best ideas, the most promising companies and the top deal makers in emerging growth finance for three days of education and networking in the nation’s premier destination for meetings and entertainment. Pioneers and industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, and management of rising issuers as well as service professionals all attend the The Growth Capital Expo to discuss significant trends in the industry.

Sunny J. Barkats, Esq., the founding partner of JSBarkats, added, “I am excited to have the opportunity to debate the pros and cons of established exemptions under the ’33 Act and new provisions under Title IV of the JOBS Act, basically, at JSBarkats we have helped many companies reach their full potential by directly tapping into their best assets, namely: Their consumers, their followers and believers and become immediately liquid, all while fully complying with SEC requirements. We quarterback offerings from a legal standpoint of view and help maximize value.”

Amarantus BioScience Obtains Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange

SUNNYVALE, Calif.–()–Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), today announced that the Berlin-Bremen Stock Exchange (BBSE) has complied with the Company’s demand to cease the unauthorized listing of its common stock, and that as of today its shares are no longer traded on the BBSE.

Sunny J. Barkats, Esq., founding partner of the law offices of JS Barkats stated, “Many small cap issuers are finding their stock listed on the Berlin-Bremen exchange despite no action on their part, and it could affect the company and its shareholders from an arbitrage standpoint. Thanks to M. Teresa Daley, the head of our litigation group, and her negotiation skills, our team of litigators has obtained the delisting of Amarantus from the Berlin exchange in an amicable fashion.”

The BBSE is one of the few exchanges in the world that allows listing and trading to occur without the consent of the listed company. The Company did not authorize or direct any BBSE broker to act as a market maker for the Company’s common stock. The Company believes that it is in the best interests of its shareholders to ensure that any listing of the Company’s common stock, whether in the U.S. or on a foreign exchange, is sanctioned by the Company so that management is in a position to ensure regulatory compliance regarding regular trading and other trading-related activities with all United States securities laws. Cessation of trading on the BBSE will not affect the Company’s common stock listing in the United States, where it trades on the OTCQB platform.

About Amarantus BioScience

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson’s disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and related nervous-system disorders. For further information please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus’ diagnostic product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus’ new product candidates, including those identified under “Risk Factors” in Amarantus’ most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

This post is also available in: Spanish